ALZAMEND NEURO, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period
ALZAMEND NEURO, INC. (ALZN) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period of 5.70 thousand shares for the 12-month period ending 2026-04-30, per its 10-K filed 2026-07-22.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod · last filed 2026-07-22
- ALZAMEND NEURO, INC. share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2025-04-30 was -2.96K shares.
- ALZAMEND NEURO, INC. share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2025-01-31 was 0.00 shares.
- ALZAMEND NEURO, INC. share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2024-10-31 was 0.00 shares.
- ALZAMEND NEURO, INC. share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2024-07-31 was 3.33K shares.
- ALZAMEND NEURO, INC. share-based compensation arrangement by share-based payment award, options, expirations in period for fiscal 2026 was 5.70K shares, a 1441.08% increase from fiscal 2025.
- ALZAMEND NEURO, INC. share-based compensation arrangement by share-based payment award, options, expirations in period for fiscal 2025 was 370.00 shares, a 48.75% decline from fiscal 2024.
- ALZAMEND NEURO, INC. share-based compensation arrangement by share-based payment award, options, expirations in period for fiscal 2024 was 722.00 shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 12 month |
|---|---|---|---|---|
| 2026-04-30 | 5.70K shares 10-K · filed 2026-07-22 | |||
| 2025-04-30 | -2.96K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-07-22 | -2.96K shares derived: sum of 2 quarters · filed 2025-07-22 | -2.96K shares derived: sum of 3 quarters · filed 2025-07-22 | 370.00 shares 10-K · filed 2025-07-22 |
| 2025-01-31 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-03-10 | 0.00 shares derived: sum of 2 quarters · filed 2025-03-10 | 3.33K shares 10-Q · filed 2025-03-10 | -3.17K shares derived: sum of 4 quarters · filed 2025-03-10 |
| 2024-10-31 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-12-11 | 3.33K shares 10-Q · filed 2024-12-11 | -3.17K shares derived: sum of 3 quarters · filed 2024-12-11 | -3.17K shares derived: sum of 4 quarters · filed 2024-12-11 |
| 2024-07-31 | 3.33K shares 10-Q · filed 2024-09-11 | -3.17K shares derived: sum of 2 quarters · filed 2024-09-11 | -3.17K shares derived: sum of 3 quarters · filed 2024-09-11 | |
| 2024-04-30 | -6.50K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-07-30 | -6.50K shares derived: sum of 2 quarters · filed 2024-07-30 | 722.00 shares 10-K · filed 2024-07-30 | |
| 2024-01-31 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-03-25 | 7.22K shares 10-Q · filed 2024-03-25 | ||
| 2023-10-31 | 7.22K shares 10-Q · filed 2023-12-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Medicus Pharma Ltd. (MDCX) | $0.010B |